Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects (LEF-2495)

This study has been completed.
Sponsor:
Information provided by:
YM BioSciences
ClinicalTrials.gov Identifier:
NCT00709254
First received: July 1, 2008
Last updated: July 2, 2008
Last verified: July 2008
  Purpose

This study was designed to assess single-dose and multiple-dose PK and safety parameters utilizing a dosage of 3 mL (500 µg/mL)AeroLEF delivered via nebulization with the AeroEclipse BAN device. The study was conducted in opioid naïve subjects who were not blocked with naloxone or other opioid receptor antagonists.


Condition Intervention Phase
Healthy
Drug: i.v. fentanyl
Drug: 3 mL AeroLEF (500 µg/1 mL)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I, 3-Period, Fasting, Bioavailability, Safety Assessment and PK Study Evaluating Single Dose Administration of i.v. Fentanyl (200 µg) and Single and Multiple Doses of 3 mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 µg/mL) Administered in Normal Healthy Subjects

Resource links provided by NLM:


Further study details as provided by YM BioSciences:

Primary Outcome Measures:
  • Adverse Events [ Time Frame: continuously ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • pharmacokinetics and bioavailability [ Time Frame: various time points ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: December 2001
Study Completion Date: January 2002
Primary Completion Date: January 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Treatment Group A
Subjects received an i.v. dose of fentanyl (200 µg)
Drug: i.v. fentanyl
single dose, 200 ug
Other Name: fetanyl citrate injection
Experimental: Treatment Group B
Subjects received a single dose of 3 mL AeroLEF (500 µg/1 mL)
Drug: 3 mL AeroLEF (500 µg/1 mL)
A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
Other Name: Aerosolized Free and Liposome-Encapsulated Fentanyl
Experimental: Treatment Group C
Subjects received multiple doses of 3 mL AeroLEF (500 µg/1 mL) every 12 hours for a total of five doses over a 3 days
Drug: 3 mL AeroLEF (500 µg/1 mL)
A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
Other Name: Aerosolized Free and Liposome-Encapsulated Fentanyl

Detailed Description:

Period I: Subjects received an i.v.dose of fentanyl (200 µg) (Treatment A).

Period II: Subjects were randomly assigned to receive either a single-dose (Treatment B) or multi-dose (Treatment C) of AeroLEF.

In the multi-dose Treatment C group, subjects received a dose of 3 mL AeroLEF every 12 hours for a total of five doses over a 3 days with a 4 week washout period before crossing over to Period III.

Period III: Subjects from Period II participated in the crossover study and receive either a multi-dose (Treatment C, 5 doses at 12 hour intervals) or a single dose (Treatment B). Subjects in Treatment B or Treatment C were instructed to continue inhalation of AeroLEF for approximately one (1) minute beyond the point of nebulizer sputter to ensure that all aerosolized medication was delivered.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non-smoking male or female with a minimum age of at least 18 years
  • Body weight with aBMI range of 18.5 - 27, with a minimum weight of at least 60 kg.
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements, as evidenced by a signed, written, Informed Consent Form.
  • Normal findings in the physical examination, vital signs (blood pressure between 100-140 - 60-90 mmHg, heart rate between 55-99 beats/min, respiration rate between 12-20 minute) and a 12 lead ECG.
  • Negative for drug abuse, nicotine, alcohol, hepatitis B-surface antigen, hepatitis C and HIV.
  • If a female of child-bearing potential, the patient must have a negative urine pregnancy test at screening and baseline.
  • No clinical laboratory values outside of the Principal Investigator's acceptable range, unless the Principal Investigator decided that the subject's values are not clinically significant.
  • Female subjects: (a) if pre-menopausal, have regular menstrual cycles (28-32 days), and (b) are not pregnant prior to study start and avoids pregnancy during the study and 1 month post drug administration, or (c) were surgically sterile for at least 6 months prior to enrollment, or (d) are post-menopausal for at least 1 year prior to enrollment.

Exclusion Criteria:

  • Known history of hypersensitivity to fentanyl.
  • Presence or history of cardiac, pulmonary, gastrointestinal, endocrine, neuromuscular, neurologic, hematological, liver or kidney disease, or any condition known to interfere with absorption, distribution , metabolism, or excretion of drugs.
  • History of drug abuse or narcotic dependency.
  • Use of prescription medication within 30 days preceding entry int the study, including any enzyme inducing/inhibitory drugs (excluding contraceptives).
  • Participating in a clinical trial with an investigational drug within 30 days preceding this trial.
  • Blood donation within 45 days preceding this trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00709254

Locations
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada
Sponsors and Collaborators
YM BioSciences
Investigators
Study Director: Diana Pilura, PhD YM BioSciences
Principal Investigator: Paul Y Tam, MD, FACP University of Toronto, Ontario, Canada
  More Information

No publications provided

Responsible Party: Ali Raza, Chief Medical Officer, YM BioSciences
ClinicalTrials.gov Identifier: NCT00709254     History of Changes
Other Study ID Numbers: LEF-2495
Study First Received: July 1, 2008
Last Updated: July 2, 2008
Health Authority: Canada: Health Canada

Keywords provided by YM BioSciences:
AeroLEF
fentanyl
pharmacokinetics
liposome
encapsulated

Additional relevant MeSH terms:
Fentanyl
Adjuvants, Anesthesia
Analgesics
Analgesics, Opioid
Anesthetics
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 19, 2014